ESLAW Estrella Immunopharma, Inc.: institutional ownership and insider trading
11 funds reported holding $257K of Estrella Immunopharma, Inc. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
ESLAW revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.31M, EPS -0.05
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.29M, EPS -0.05
- Quarter ended Dec 31, 2025: revenue n/a, net income −$613K, EPS -0.01
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.80M, EPS -0.13
Famous investors holding ESLAW
- D. E. Shaw (D. E. Shaw & Co.): $12.5K, 0.0% of the portfolio
Largest institutional holders of ESLAW
- BOOTHBAY FUND MANAGEMENT, LLC — $197K
- D. E. Shaw & Co., Inc. — $12.5K
- ATW SPAC MANAGEMENT LLC — $9.49K
- SkyView Investment Advisors, LLC — $8.00K
- Yakira Capital Management, Inc. — $6.02K
- Robertson Stephens Wealth Management, LLC — $5.60K
- WHITEBOX ADVISORS LLC — $5.50K
- Clear Street Group Inc. — $4.43K
- CITIGROUP INC (C, C-PN) — $3.90K
- TORONTO DOMINION BANK (TD, TDBCP) — $2.81K
Recent ESLAW insider trades
- Oct 7, 2025: Xu Jiandong bought 2,100 shares ($2.59K)